MRS and 11C-methionine PET/CT in the Diagnosis of Glioma

Not Applicable

Completed

• Conditions: Glioma

• Registration Number: NCT03009318
• Lead Sponsor: Huashan Hospital

Brief Summary

MET PET and MRS are often performed as imaging tool for the differential diagnosis of gliomas. But both techniques have limitations causing misdiagnosis; thus, the investigators tried to combine these two imaging tools to study whether the combination of MET PET and MRS could raise the diagnosis ability of the radiological diagnosis of gliomas.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-01
• Primary Completion: 2016-09
• Study First Submitted: 2016-12-29
• Study First Submitted QC: 2016-12-31
• Study First Posted: 2017-01-04
• Study Completion: 2017-12
• Status Verified: 2018-04
• Last Update Submitted: 2018-04-05
• Last Update Posted: 2018-04-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Patients with non-enhancing supratentorial lesions shown by contrast-enhanced MRI
2. No surgery, chemotherapy or radiotherapy history
3. All patients gave written informed consent.

Exclusion Criteria

1. Patients with infratentorial Neoplasms
2. Patients with enhancing supratentorial lesions
3. Recurrent gliomas after surgery
4. Primary gliomas with history of radiotherapy or chemotherapy
5. History of malignant tumours at any body site
6. Inability to give informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Sensitivity of the combination of MRS and 11C-MET PET/CT	5 years

Secondary Outcome Measures

Name	Time	Method
The relationship between 11C-MET PET/CT results and molecular pathogeneses	5 years

Trial Locations

Locations (1)

Huashan hospital, Fudan university; 🇨🇳 Shanghai, China